Q&A

De-Risking Your Bioconjugate's Path To Clinical Manufacturing

Source: Lonza
GettyImages-1405217456 woman in lab

The bioconjugate market has made significant progress since the approval of the first antibody drug conjugate (ADC) in 2000. Now, these innovative therapies make up approximately 10% to 15% of the biologics market. Yet, despite the continued advancements in this space, drug developers pursuing bioconjugate modalities continue to face a wide range of challenges on their path to market. Experience, expertise, and a toolbox of solutions that can accommodate your product’s unique needs are critical in the early stages of development to mitigate risks later when the cost of failure is higher.

Lonza Pharma & Biotech’s Dr. Raphael Frey, team lead for early development of bioconjugates, and Dr. Sandro Holzer, head of process development of bioconjugates, hosted the webinar From Early Development into Clinic – De-risking a Bioconjugate’s Journey. In it, Dr. Frey and Dr. Holzer discussed the challenges when moving a bioconjugate candidate from early development to clinic as well as key considerations for de-risking this journey. Two case studies were presented to demonstrate how Lonza has worked with clients to overcome obstacles in their path to the bioconjugate market.

Download the full article to review the Q&A session held after the event, where the presenters addressed attendee questions about the details of the presentation.

VIEW THE Q&A!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Drug Discovery Online? Subscribe today.

Subscribe to Drug Discovery Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Drug Discovery Online